BMC TV delivers Paralympic coverage to UK with ADVA FSP 150
ADVA (FSE: ADV) today announced that BMC TV deployed its FSP 150 Carrier Ethernet technology to transport coverage of the Paralympic Games from Tokyo to London. The robust, low-power solution empowered BMC TV to cost-effectively provide highly reliable services, enabling hundreds of hours of live broadcasting on high-definition television and online streams. The close support of ADVA’s team, together with the ease of use of its FSP 150 device, helped to ensure the success of the project. Fiber optic solutions provider Fibre Technologies also played a key role.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005059/en/
ADVA’s FSP 150 technology helped BMC TV bring coverage of the Tokyo Paralympics to an audience of over 20 million people. (Photo: Business Wire)
“We’re proud to have helped bring high-quality coverage of the Paralympics to a UK audience of over 20 million. By harnessing ADVA’s edge Ethernet equipment, we were able to maintain superb network uptime and ensure an exceptional viewer experience,” said Tim Horsfield, director, BMC TV. “We were very impressed with how straightforward ADVA’s solution was to deploy. It also simplifies operations by using established OAM procedures, while its fanless design and low power consumption help to minimize carbon footprint. What’s more, ADVA’s team was always on hand to lend their support and expertise.”
Using the ADVA FSP 150-XG108 Series of Layer 2 service demarcation and aggregation devices, BMC TV was able to provide highly reliable and cost-effective broadcast services. This allowed Channel 4, one of Britain’s biggest television networks, to deliver a rich and immersive viewing experience with every sport at the Tokyo 2020 Paralympic Games covered live and in full. The ADVA FSP 150-XG108 Series enabled BMC TV to efficiently aggregate 1Gbit/s services into 10Gbit/s wavelengths. With its small footprint, redundant power supply and hardware-assisted synchronization, the solution is optimized for cost-sensitive high-bandwidth edge applications.
“The Tokyo Paralympics entertained and inspired millions of viewers. That’s why enabling BMC TV to transmit comprehensive coverage of the games was so rewarding for our team. Our technology and support were key to making this project a major success,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “Our solution offers advanced demarcation and aggregation capabilities alongside a rich feature set, including hardware-assisted synchronization and zero-touch provisioning for quick and easy service activation. Once again, our FSP 150 technology has shown itself to be in a class of its own for fast and seamless deployment of cost-sensitive Carrier Ethernet services.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About BMC TV
BMC TV are Media Moving experts™. Specialists in IP transport of Broadcast Media over Fibre, Satellite and the Cloud. BMC TV helps broadcasters with connectivity solutions for sports, news and broadcast special events and to deliver this content in multiple formats, to multiple destinations, all around the world. www.bmcuk.tv.
About FTL
Fibre Technologies Ltd (FTL) based in Berkshire, are a highly accredited, multi division, solutions integrator, who specialise in providing the best possible solutions using the latest technology from their chosen partners. They are a financially independent company with a customer base spanning Telco’s, ISP’s, MSP’s, Mod/Government, Education, Industrial and enterprise clients. www.fibre.co.uk.
Published by:
ADVA Optical Networking SE, Munich, Germany
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005059/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom